BYON 3521
Alternative Names: BYON-3521Latest Information Update: 28 Apr 2025
At a glance
- Originator Syntarga
- Developer Byondis
- Class Antineoplastics; Drug conjugates; Monoclonal antibodies
- Mechanism of Action Alkylating agents; DNA synthesis inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in Belgium (IV, Infusion)
- 28 Apr 2025 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease) in United Kingdom (IV, Infusion)
- 25 Sep 2024 BYON 3521 is still in phase-I for Solid-tumours (Late-stage disease, Metastatic disease) in United Kingdom and Belgium (IV, Infusion) (NCT05323045)